^
    21d
    SELECT-NK-THYM: Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • MSLN (Mesothelin) • CD5 (CD5 Molecule)
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    1m
    P-CD19CD20-ALLO1-001: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, Poseida Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RG6540 • rimiducid (AP1903)
    1m
    Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)
    |
    HER-2 negative
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • rimiducid (AP1903)
    2ms
    Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    2ms
    P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=275, Active, not recruiting, Poseida Therapeutics, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    RG6538 • rimiducid (AP1903)
    2ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Recruiting, Genentech, Inc. | Initiation date: Feb 2026 --> Jun 2026
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    2ms
    Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum (clinicaltrials.gov)
    P1/2, N=10, Not yet recruiting, M.D. Anderson Cancer Center
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    3ms
    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Pharmacodynamics, and Efficacy of P-CD19CD20-ALLO1 in Participants With Severe, Treatment-refractory Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov)
    P1, N=162, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • RG6540 • rimiducid (AP1903)
    4ms
    Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=52, Terminated, Regeneron Pharmaceuticals | Phase classification: P1/2 --> P1 | N=151 --> 52 | Suspended --> Terminated; Due to a Dose Limiting Toxicity.
    Phase classification • Enrollment change • Trial termination
    |
    BPX-601 • rimiducid (AP1903)
    6ms
    Using the iCasp9 suicide strategy to control the growth and function of genome-edited B cells with redirected antigen specificity. (PubMed, Mol Ther Oncol)
    Although AP1903 treatment strongly curbed edited cell survival, this was constantly followed by the selection of resistant cells with lowered expression of both iCasp9 and the therapeutic antibody cassette. Therefore, in adoptive immunotherapy protocols, the iCasp9/AP1903 safety switch could stand as an efficient neoadjuvant therapy, as well as a rheostat to modulate the infusion of a therapeutic molecule.
    Journal • IO biomarker
    |
    CASP9 (Caspase 9)
    |
    rimiducid (AP1903)
    6ms
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19 | Trial completion date: Mar 2043 --> Jul 2040 | Trial primary completion date: Mar 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)
    7ms
    P-BCMA-ALLO1-001: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=275, Recruiting, Poseida Therapeutics, Inc. | Trial completion date: Dec 2039 --> Mar 2042 | Trial primary completion date: Dec 2027 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    RG6538 • rimiducid (AP1903)